Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05495269 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
A Phase 2 study, sponsored by Qlaris Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05495269 is a Phase 2 study that has completed, run by Qlaris Bio. The registered enrollment target is 2 participants.
The verdict
NCT05495269, a Phase 2 study, has completed, sponsored by Qlaris Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Open-label study of an investigational product (IP), QLS-101, with 28-day every morning (QAM) dosing to both eyes (OU) in adolescents with SWS who have clinical evidence of glaucoma and/or ocular hypertension (OHT) related to SWS elevated EVP in at least one eye.
Interventions
- DRUG QLS-101 ophthalmic solution, 2.0 %
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-11-23 |
| Est. Completion | 2023-03-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05495269
The ClinicalTrials.gov registry entry for NCT05495269 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qlaris Bio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QLS-101 ophthalmic solution, 2.0 % is the first listed.
NCT05495269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05495269 about?
NCT05495269 is a clinical study titled "Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)". Open-label study of an investigational product (IP), QLS-101, with 28-day every morning (QAM) dosing to both eyes (OU) in adolescents with SWS who have clinical evidence of glaucoma and/or ocular hypertension (OHT) related to SWS elevated EVP in at least one eye.
What is the current status of trial NCT05495269?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2022-11-23. Estimated completion is 2023-03-20.
What interventions are being tested in trial NCT05495269?
The interventions under investigation include: QLS-101 ophthalmic solution, 2.0 % (DRUG).
Who is sponsoring clinical trial NCT05495269?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.